Optimal Design Applied to Hematological Toxicity-Induced Anticancer Treatment

Camille Vong(Uppsala University), Andrew C. Hooker(Uppsala University), Joakim Nyberg(Uppsala University), Mats O. Karlsson(Uppsala University), Lena E. Friberg(Uppsala University)

Unknown

January 1, 2014

Cited by 0

Related Papers

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

|The Lancet|2023|508

The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections

|Intensive Care Medicine|2017|149

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

|Pharmaceutics|2022|92

PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool

|Computer Methods and Programs in Biomedicine|2012|86

Methods and software tools for design evaluation in population pharmacokinetics–pharmacodynamics studies

|British Journal of Clinical Pharmacology|2014|82